Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent (Siponimod): An OTIS Observational Pregnancy Surveillance Study
Sponsor: Novartis Pharmaceuticals
A observational or N/A phase clinical study on Multiple Sclerosis, this trial is actively recruiting participants. The trial is conducted by Novartis Pharmaceuticals and has accumulated 11 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
Jun 2023 — Jun 2024 [monthly]
Recruiting
-
Feb 2023 — Jun 2023 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Jul 2022 — Feb 2023 [monthly]
Recruiting
-
Mar 2022 — Jul 2022 [monthly]
Recruiting
-
Feb 2022 — Mar 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Feb 2022 [monthly]
Not Yet Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .